Takeda Pharmaceutical (TAK) News Today → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free TAK Stock Alerts $13.22 -0.09 (-0.68%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 11:12 AM | finance.yahoo.comTakeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infectionMay 14, 2024 | finance.yahoo.comScilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent DisputeMay 14, 2024 | finance.yahoo.comUpdate: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent DisputeMay 14, 2024 | businesswire.comTakeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual MeetingMay 13, 2024 | businesswire.comAC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's DiseaseMay 13, 2024 | bizjournals.comMeet the Mass. life science CEOs with the largest pay packagesMay 9, 2024 | finance.yahoo.comJapan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%May 9, 2024 | marketbeat.comTakeda Pharmaceutical (NYSE:TAK) Reaches New 1-Year Low at $12.77Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month Low at $12.77May 9, 2024 | seekingalpha.comTakeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call PresentationMay 9, 2024 | investorplace.comTAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023May 9, 2024 | reuters.comJapan's Takeda Pharma says full-year profit slumps 56%May 8, 2024 | forbes.comA Five-Pillar Process To Develop Sales LeadersMay 8, 2024 | marketwatch.comTakeda Pharmaceutical's Fourth-Quarter Profit Expected to Have More Than Tripled -- Earnings PreviewMay 2, 2024 | marketbeat.comTakeda Pharmaceutical (TAK) Set to Announce Earnings on ThursdayTakeda Pharmaceutical (NYSE:TAK) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 1, 2024 | marketbeat.comY.D. More Investments Ltd Has $17.90 Million Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)Y.D. More Investments Ltd cut its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,254,591 shares of the company'April 30, 2024 | finance.yahoo.comBeacon Biosignals and Takeda Launch Strategic Collaboration to Advance Neurobiomarkers and Endpoints for Sleep DisordersApril 30, 2024 | marketbeat.comabrdn plc Takes Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)abrdn plc purchased a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 105,073 shares of the compaApril 27, 2024 | marketbeat.comTakeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Down 26.5% in AprilTakeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) was the target of a significant decrease in short interest in April. As of April 15th, there was short interest totalling 5,970,000 shares, a decrease of 26.5% from the March 31st total of 8,120,000 shares. Based on an average daily volume of 1,850,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 0.2% of the company's stock are short sold.April 26, 2024 | markets.businessinsider.comTakeda Reports Positive CHMP Opinion For Fruquintinib - Quick FactsApril 26, 2024 | businesswire.comTakeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal CancerApril 26, 2024 | marketbeat.comFederated Hermes Inc. Has $6.26 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)Federated Hermes Inc. reduced its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 22.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 438,324 shares of the company's stock after selling 125,449 shares during the period. FederatedApril 25, 2024 | msn.comTakeda said to have left industry trade group BIOApril 25, 2024 | marketbeat.comTakeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month Low at $13.08Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month Low at $13.08April 24, 2024 | msn.comJapan’s SMBC joins JV to support drug discovery start-upsApril 23, 2024 | finance.yahoo.comNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive DisorderApril 22, 2024 | prnewswire.comTakeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery ProgramsApril 19, 2024 | benzinga.comExploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In PharmaceuticalsApril 18, 2024 | finance.yahoo.comU.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s DiseaseApril 18, 2024 | businesswire.comU.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's DiseaseApril 16, 2024 | finance.yahoo.comTakeda Pharmaceutical Company Limited (4502.T)April 15, 2024 | marketbeat.comTakeda Pharmaceutical (NYSE:TAK) Hits New 52-Week Low at $13.19Takeda Pharmaceutical (NYSE:TAK) Hits New 1-Year Low at $13.19April 8, 2024 | businesswire.comTakeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional FoodApril 6, 2024 | marketbeat.comPacer Advisors Inc. Sells 897,979 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)Pacer Advisors Inc. lessened its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 96.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 28,766 shares of the company's stock after selling 8April 4, 2024 | marketbeat.comTakeda Pharmaceutical Company Limited (NYSE:TAK) is XY Capital Ltd's 3rd Largest PositionXY Capital Ltd increased its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 432.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 765,137 shares of the company's stock after buying anApril 2, 2024 | businesswire.comOncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory BoardApril 1, 2024 | finance.yahoo.comAculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEOMarch 28, 2024 | marketbeat.comTakeda Pharmaceutical (NYSE:TAK) Trading Down 2.4%Takeda Pharmaceutical (NYSE:TAK) Stock Price Down 2.4%March 28, 2024 | usnews.comPuerto Rico Declares Dengue Epidemic as Cases ClimbMarch 27, 2024 | prnewswire.comEmpathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAEMarch 26, 2024 | businesswire.comTakeda Announces Candidates for Board of Directors at Upcoming Shareholders MeetingMarch 26, 2024 | markets.businessinsider.comTakeda Announces Approval Of ADZYNMA Intravenous Injection 1500 In JapanMarch 26, 2024 | finance.yahoo.comTakeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)March 21, 2024 | finance.yahoo.comThe Leadership Development Group Releases Guide on Talent Management Strategies For Post-Milestone GrowthMarch 19, 2024 | markets.businessinsider.comTakeda : FDA Approves SNDA For Iclusig In Adult Patients With Newly Diagnosed Ph+ ALLMarch 19, 2024 | businesswire.comTakeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALLMarch 18, 2024 | businesswire.comAdvanced Infusion Care (AIC) Now Offers Takeda's GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] and ARALAST® NP [Alpha1-Proteinase Inhibitor (Human)]March 15, 2024 | finanznachrichten.deTakeda Pharmaceuticals: Takeda's 'In Their Shoes' Program Sheds Light on IBD Challenges in South AfricaMarch 14, 2024 | marketbeat.comTakeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest UpdateTakeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) saw a large drop in short interest during the month of February. As of February 29th, there was short interest totalling 6,260,000 shares, a drop of 21.7% from the February 14th total of 7,990,000 shares. Based on an average daily volume of 1,880,000 shares, the days-to-cover ratio is currently 3.3 days. Approximately 0.2% of the company's shares are short sold.March 13, 2024 | finance.yahoo.comProstate Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033March 13, 2024 | finance.yahoo.comTakeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (Ad)Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it. Click on Adam's shiny forehead for more details. TAK Media Mentions By Week TAK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TAK News Sentiment▼0.240.42▲Average Medical News Sentiment TAK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TAK Articles This Week▼65▲TAK Articles Average Week Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALNY News Today GMAB News Today BMRN News Today TEVA News Today BGNE News Today VTRS News Today SRPT News Today RDY News Today UTHR News Today ZTS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:TAK) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyDems have chosen Biden replacement?Paradigm Press41 banks launch ‘crypto dollar’Stansberry ResearchMost important medical advance in 100 yearsThe Oxford Club4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Company Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
